S2H97
An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.
General information
S2H97 is a human monoclonal antibody recognizing a cryptic epitope within Spike RBD from various sarbecovirus clades including SARS-CoV-2. It does not inhibit ACE2 binding but has neutralization capacity (likely via premature conversion of Spike into the post-fusion state). S2H97 displayed protective effect in an animal challenge (Starr et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Spike protein Spike variant Protein factor In vitro Antibody |
Vero E6-TMPRSS2 cells; SARS-CoV-2 Spike-pseudotyped viruses (including WA1/2020 D614G or Omicron) | 49.96 | The antibody neutralizes Omicron variant of SARS-CoV-2 in vitro (less potently compared to the Wuhan strain). |
Dec/23/2021 |
|
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Spike protein ACE2 Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism In silico |
in silico; Vero E6 cells; 293T-ACE2 cells; Syrian hamsters; Various (VSV)Spike-pseudotyped viruses (including SARS-CoV-2); modified live SARS-CoV-2 (based on 2019-nCoV/USA_WA1/2020) | 49.96 | The antibody bound Spike RBD of various sarbecovirus clades including SARS-CoV-2 in vitro. It neutralized various SARS-CoV-2 variant pseudoviruses. It was shown to bind a cryptic epitope within RBD, thus likely inducing premature conversion of Spike into the post-fusion state. The antibody reduced lung viral loads in a hamster model. |
Jul/14/2021 |
